Comparative Pharmacology
Head-to-head clinical analysis: BYDUREON versus BYDUREON PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYDUREON versus BYDUREON PEN.
BYDUREON vs BYDUREON PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety.
2 mg subcutaneously once every 7 days (weekly).
2 mg subcutaneously once every 7 days (weekly)
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 hours after subcutaneous administration for immediate-release exenatide; however, BYDUREON (extended-release) exhibits a prolonged half-life of approximately 2 weeks (mean range 14-20 days) due to encapsulation in microspheres.
Terminal elimination half-life is 2.4 hours following subcutaneous administration; due to extended-release microspheres, systemic exposure is sustained over 10 weeks with multiple dosing (effective half-life ~2 weeks).
Excreted primarily via renal proteolytic degradation; intact exenatide is eliminated renally. Renal clearance accounts for approximately 80% of total clearance; fecal elimination is negligible (<5%).
Renal excretion of intact exenatide via glomerular filtration and proteolytic degradation; approximately 100% of administered dose eliminated via renal pathways (urine) as intact peptide and metabolites.
Category C
Category C
Antidiabetic
Antidiabetic